Is Regeneron a Buy Before Nov. 3?

Regeneron Pharmaceuticals (NASDAQ: REGN) made headlines recently after President Trump, diagnosed with COVID-19 earlier this month, took the biotech's investigational treatment. Trump, who also took other experimental medications for the illness, went on to call Regeneron's antibody cocktail "a cure." And he said he would help bring the treatment to Americans as quickly as possible.

Now, investors might be wondering whether they should buy shares of Regeneron before the presidential election. Will a Trump victory be better news for the company than a victory by Democratic challenger Joe Biden? Or will Biden's plan to conquer the coronavirus outbreak also equal strong support for Regeneron? Let's take a closer look at the situation.

Image source: Getty Images.

Continue reading

Source Fool.com